<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01302379</url>
  </required_header>
  <id_info>
    <org_study_id>U54 CA155435-01 Project 3</org_study_id>
    <nct_id>NCT01302379</nct_id>
  </id_info>
  <brief_title>Reach for Health Study: Obesity-related Mechanisms and Mortality in Breast Cancer Survivors</brief_title>
  <official_title>Obesity-related Mechanisms and Mortality in Breast Cancer Survivors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This objective of this randomized controlled trial is to conduct a 2x2 test of a lifestyle
      intervention and metformin (a drug used to treat diabetes) to investigate how these
      treatments, alone or in combination, affect biomarkers associated with breast cancer
      survival. The Reach for Health Study will enroll 340 overweight/obese, postmenopausal breast
      cancer survivors. After completing the screening process and baseline measures, participants
      will be randomized in equal numbers to: (1) placebo, (2) metformin, (3) lifestyle
      intervention and placebo, or (4) lifestyle intervention and metformin. The interventions will
      last for 6 months. Concentrations of circulating biomarkers will be assessed at baseline and
      6 months.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>August 2011</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biological markers associated with breast cancer survival</measure>
    <time_frame>Baseline, 6 months</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">333</enrollment>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>Metformin + lifestyle intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + lifestyle intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin + standard dietary guidelines</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + standard dietary guidelines</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Week 1: 500 mg at dinner time Weeks 2-4: 1000 mg at dinner time Weeks 5+: 500 mg in morning; 1000 mg at dinner time</description>
    <arm_group_label>Metformin + lifestyle intervention</arm_group_label>
    <arm_group_label>Metformin + standard dietary guidelines</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Week 1: 1 pill at dinner time Weeks 2-4: 2 pills at dinner time Weeks 5+: 1 pill in morning; 2 pills at dinner time</description>
    <arm_group_label>Placebo + lifestyle intervention</arm_group_label>
    <arm_group_label>Placebo + standard dietary guidelines</arm_group_label>
    <other_name>Sugar pill</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Lifestyle intervention</intervention_name>
    <description>Telephone-based lifestyle intervention (dietary change and physical activity) for weight loss.</description>
    <arm_group_label>Metformin + lifestyle intervention</arm_group_label>
    <arm_group_label>Placebo + lifestyle intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Standard printed dietary guidelines</intervention_name>
    <description>Set of standard health education materials provided to participants at single time point (immediately after randomization)</description>
    <arm_group_label>Metformin + standard dietary guidelines</arm_group_label>
    <arm_group_label>Placebo + standard dietary guidelines</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI at least 25.0 kg/m2

          -  Diagnosed with Stage I, II, or III breast cancer within past 5 years

          -  Treatment with total mastectomy or breast-sparing surgical removal of cancer with
             clear macroscopic margins, and axillary dissection, followed by adjuvant breast
             radiation

          -  Not scheduled for or currently undergoing chemotherapy

          -  Accessible geographically and by telephone

          -  Able to communicate dietary and physical activity data via telephone

          -  If taking statins, tamoxifen, or aromatase inhibitors; able and willing to remain on
             treatment for 6-month study period

          -  Post-menopausal at diagnosis

        Exclusion Criteria:

          -  Preliminary bloodwork outside of specified ranges

          -  Evidence of renal insufficiency, liver disease, or congestive heart failure

          -  Currently taking corticosteroid pills or steroid hormone therapy (including vaginal
             estrogen creams)

          -  Recent initiation (&lt; 3 months ago) of thiazides or Î²-blockers

          -  Taking insulin or other antidiabetic drug

          -  Other primary or recurrent invasive cancer in past 10 years

          -  Unable to commit to study requirements
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Moores UCSD Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2011</study_first_submitted>
  <study_first_submitted_qc>February 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2011</study_first_posted>
  <last_update_submitted>December 8, 2015</last_update_submitted>
  <last_update_submitted_qc>December 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Ruth E. Patterson</investigator_full_name>
    <investigator_title>Professor, Department of Family &amp; Preventive Medicine</investigator_title>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Survival</keyword>
  <keyword>Weight loss</keyword>
  <keyword>Metformin</keyword>
  <keyword>Biological markers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

